Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zilurgisertib · Atebrioz, INCB-000928

Small molecule · Inhibitor of activin A receptor type I (ALK2) (ACVR1) · developed by Mirum

Approved FDA, Sep 2026
1 Registered trials

What is Zilurgisertib?

Zilurgisertib is an oral, selective small-molecule inhibitor of ALK2 (ACVR1), including wild-type and the pathogenic R206H mutant form. By blocking ALK2 signaling in the bone morphogenetic protein pathway, it reduces endochondral bone formation. It is studied in fibrodysplasia ossificans progressiva.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Atebrioz, INCB-000928
Drug type
Small molecule
Targets
activin A receptor type I (ALK2) (ACVR1)
Mechanism
Inhibitor of activin A receptor type I (ALK2) (ACVR1)
Pathways
BMP signaling, endochondral bone formation
Therapy area
Musculoskeletal
Developer
Mirum
In trials of
INCY
FDA status
Approved as Atebrioz (September 25, 2026), NDA221198 · FDA label
UNII
L5Z9S25HO2

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 9, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05090891 Phase 2 Fibrodysplasia Ossificans Progressiva (FOP) Recruiting INCY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fibrodysplasia Ossificans Progressiva (FOP)

Sources

Updated Nov 22, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.